Shanghai Henlius Biotech Inc Class H 02696
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- HK$22.75
- Day Range
- HK$22.50–22.70
- 52-Week Range
- HK$9.60–23.45
- Bid/Ask
- HK$22.60 / HK$22.65
- Market Cap
- HK$12.28 Bil
- Volume/Avg
- 818,800 / 473,908
Key Statistics
- Price/Earnings (Normalized)
- 15.92
- Price/Sales
- 2.00
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,637
- Website
- https://www.henlius.com
Comparables
Valuation
|
Metric
|
02696
|
4157
|
688062
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.92 | 358.64 | — |
Price/Book Value | 4.43 | 9.16 | 5.09 |
Price/Sales | 2.00 | 74.61 | 71.82 |
Price/Cash Flow | 10.23 | 182.02 | — |
Price/Earnings
02696
4157
688062
Financial Strength
|
Metric
|
02696
|
4157
|
688062
|
|---|---|---|---|
Quick Ratio | 0.32 | 19.37 | 1.53 |
Current Ratio | 0.49 | 20.34 | 1.78 |
Interest Coverage | 6.49 | 136.44 | −32.55 |
Quick Ratio
02696
4157
688062
Profitability
|
Metric
|
02696
|
4157
|
688062
|
|---|---|---|---|
Return on Assets (Normalized) | 7.67% | 4.77% | −24.26% |
Return on Equity (Normalized) | 33.96% | 5.29% | −41.90% |
Return on Invested Capital (Normalized) | 12.87% | 3.05% | −26.98% |
Return on Assets
02696
4157
688062
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Bwrktggx | Gzdm | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tkxfjrdm | Jkczgyk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zwmgbhwp | Jjfqp | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bwnpcfpk | Wygdnx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Jnhnsywfp | Rbft | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qbwgmcsl | Zgmk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Pkssmkg | Kycc | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Mfrbwhx | Tqxv | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yqnqmpms | Twfrhj | $13.4 Bil | |||
| Incyte Corp
INCY
| Dkhngzggd | Wpkzgxx | $12.7 Bil |
United States